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Background & Aims: Ustekinumab, a human monoclonal antibody against the p40 subunit 
of interleukins-12 and -23, is effective in inducing and maintaining remission in patients with 
luminal Crohn's disease (CD). We assessed the efficacy and safety of subcutaneous 
ustekinumab in patients with anti-tumor necrosis factor (anti-TNF) refractory CD. 
Methods: We performed a retrospective observational study, collecting data from the Groupe 
d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif on 122 consecutive 
patients with active CD refractory to anti-TNF therapy who received at least 1 subcutaneous 
injection of ustekinumab from March 2011 to December 2014, in 20 tertiary centers in 
Europe. Subjects were followed for at least 3 months. The primary outcome was clinical 
benefit, defined as reductions in symptoms and biochemical markers of CD and complete 
weaning from steroids, without surgery or immunosuppressant therapies. 
Results: Seventy-nine patients (65%) had a clinical benefit within 3 months of receiving 
ustekinumab. Concomitant immunosuppressant therapy at study inclusion increased the odds 
for a clinical benefit from ustekinumab (odds ratio, 5.43; 95% confidence interval, 1.14–
25.77; P=.03). Over a median follow-up period of 9.8 months (inter-quartile range, 5.3–14.5 
months), the cumulative probabilities that patients maintained the clinical benefit for 6 and 12 
months after introduction of ustekinumab were 93% and 68%, respectively. 
Conclusions: Almost two thirds of patients with CD refractory to at least 1 anti-TNF agent 
receive clinical benefit from ustekinumab therapy, not requiring steroids for up to 12 months 
afterward. While we await results from ongoing trials, ustekinumab can be considered for use 
in these patients. 
KEY WORDS: IL12, IL23, inflammatory bowel disease, immunosuppressant 
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INTRODUCTION 
Crohn’s disease (CD) is a chronic inflammatory bowel disorder that alternates 
between periods of disease activity and clinical remission. Conventional immunosuppressants 
- thiopurines1 and methotrexate2 - and tumor necrosis factor (TNF) antagonists – infliximab 
and adalimumab3,4 - are the main therapeutic agents to obtain long term clinical remission and 
prevent irreversible intestinal damage and disability5,6. Although anti-TNF therapies have 
been shown to be effective in the medical management of CD patients, a persistent response is 
not obtained in certain patients. Controlled trials have shown that a primary response is not 
achieved in approximately 20 to 40% of patients with infliximab and adalimumab, and that up 
to 40% of patients who initially respond to the anti-TNF induction regimen will subsequently 
lose response over time. 7,8,9 Moreover, several anti-TNF side effects such as drug reactions, 
infections or paradoxical manifestations can also lead to treatment discontinuation10,11. 
Therefore, the number of patients with CD who are refractory to anti-TNF therapies and 
conventional immunosuppressants is increasing.  
New drug options with alternative modes of action are now expected in this 
population. Recently, the anti-integrin agent vedolizumab was shown to be effective for CD 
following anti-TNF failure.12 Ustekinumab, a monoclonal antibody against the p40 subunit of 
interleukin-12 and interleukin-23 that targets both the T-helper 1 and T-helper 17 pathways 
involved in the pathogenesis of CD has also been explored. In a phase II study including 526 
CD patients refractory to anti-TNF, ustekinumab has shown to be more effective than placebo 
for inducing and maintaining a clinical response.13 It is important to note that in this trial 
patients were randomly assigned to receive intravenous ustekinumab induction followed by 
subcutaneous maintenance. In France, subcutaneous ustekinumab has only been licensed to 
treat refractory psoriasis. Since 2011, subcutaneous ustekinumab is also occasionally used for 
patients with CD who are refractory to conventional immunosuppressants and anti-TNF. The 
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aim of the present study was to assess the benefit and safety of subcutaneous ustekinumab in a 
multicenter cohort of patients with refractory anti-TNF CD. 
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METHODS
Selection of patients 
A retrospective observational study was performed in tertiary French and Swiss 
centers affiliated with the Groupe d'Etude Thérapeutique des Affections Inflammatoires du 
tube Digestif (GETAID). All consecutive patients with active CD who received at least one 
subcutaneous injection of ustekinumab from March 2011 to December 2014 and with a 
follow-up of at least three months, were included in the study. Patients who received 
ustekinumab in a controlled trial were excluded from the analysis. The protocol was approved 
by the Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le 
domaine de la Santé (CCTIRS N°15.177). All authors had access to the study data and 
reviewed and approved the final manuscript. 
Data collection 
The date of inclusion corresponded to the first administration of ustekinumab. Patient 
files were retrospectively reviewed and demographic, biological, and endoscopic data were 
obtained from the medical records.  
The following characteristics were anonymously recorded for each included patient:  
age at inclusion, gender, duration of disease, the location and phenotype of CD according to 
the Montreal classification14, smoking status, number of previous intestinal resections, prior 
exposure to CD treatment including conventional immunosuppressants (thiopurines, 
methotrexate) and anti-TNF (infliximab, adalimumab, certolizumab pegol or golimumab),  
type of response (non-primary response, secondary loss of response, intolerance), occurrence 
of paradoxical skin lesions during anti-TNF, main indication for beginning ustekinumab 
(luminal or perianal CD), induction and maintenance doses, duration of ustekinumab 
treatment, association with immunosuppressants or steroids at inclusion, C-reactive protein 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
ϭϬ

(CRP) levels (elevated if above 5 mg/L) and endoscopic findings at inclusion and during 
follow-up. 
Outcomes 
The primary objective was to assess percentage of patients with a clinical benefit from 
ustekinumab after three months. A clinical benefit was defined as a significant improvement 
in CD-related clinical symptoms and laboratory tests assessed by the patient’s physician 
leading to continued ustekinumab treatment, associated with complete weaning from steroids 
if they were being taken at inclusion, without surgery or immunosuppressant introduction. 
Secondary outcomes were: (1) biologic and endoscopic response (defined as a 
significant reduction in the number of visible ulcerations) and mucosal healing (defined as a 
lack of any visible ulcerations or friable mucosa), (2) the identification of predictive factors of 
a ustekinumab induced clinical benefit at three months, (3) rates of sustained clinical benefit 
(without surgery, steroids or immunosuppressant introduction) at 6 and 12 months in 
ustekinumab initial responders, (4) evolution of patients without a clinical benefit from 
ustekinumab at three months, (5) evolution of anti-TNF induced paradoxical skin lesions and 
(6) the safety of ustekinumab. The rate of ustekinumab optimization was also recorded, but 
was not considered to be a loss of clinical benefit. 
To determine safety, all adverse events, defined as any significant event that occurred 
from the date of inclusion to the last follow-up, were recorded. Severe adverse events were 
defined as any adverse event that resulted in hospitalization or extension of the hospital stay, 
was fatal or life threatening, or led to a significant disability. 
Statistical analysis 
Descriptive statistics were used to analyze baseline characteristics. Medians with 
interquartile ranges (IQR) or means with standard deviations (SD) were calculated for 
continuous data, and percentages were computed for discrete data. The Kaplan-Meier method 
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was used to assess a sustained clinical benefit from ustekinumab over time. Univariate and 
multivariate logistic regression were performed to identify predictive factors of a clinical 
benefit to ustekinumab at three months, expressed as odds ratios (OR) with 95% confidence 
intervals (CI). Three subgroups of patients according to the cumulative ustekinumab dose 
administered during the first two months (less than 90mg, between 135 and 180mg and more 
than 225mg) were created and incorporated in the logistic regression. Variables with a p value 
below 0.10 were used for multivariate analysis. A p value of 0.05 was considered to be 
significant. 
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RESULTS 
Patient characteristics 
From March 2011 to December 2014, 135 CD patients with active disease received at 
least one subcutaneous ustekinumab injection in 20 GETAID centers in France and 
Switzerland. Thirteen patients without a follow-up of at least three months were excluded and 
122 patients were included (Figure 1A). 
The baseline demographic and clinical characteristics are presented in Table 1. Eighty-
seven (71%) patients were women, the median age at inclusion was 33.8 years old (IQR: 
27.5-43.9) and the median duration from CD diagnosis to inclusion was 11.5 years (IQR: 6.9-
17.1). Seventy-five (62%) patients had undergone prior intestinal resection. One hundred 
nineteen (98%) patients had experienced failure or intolerance to thiopurines or methotrexate 
and at least one anti-TNF agent (infliximab or adalimumab) had failed in 122 (100%) patients, 
including 112 (92%) who had received both infliximab and adalimumab, 45 (37%) who had 
received three anti-TNF agents (42 exposed to infliximab, adalimumab and certolizumab, and 
three to infliximab, adalimumab and golimumab) and two (2%) who had received four anti-
TNF agents.  
Ustekinumab was given to 110 (90%) patients for luminal CD and to 12 (10%) for 
perianal disease. At inclusion 72/104 (69%) patients had elevated CRP levels and active 
endoscopic lesions were observed in all 78 patients who were assessed at inclusion, including 
77 with ulcerations associated with an inflammatory passable stricture in 17 cases and a non-
passable stricture in one case. 
Thirteen different ustekinumab induction regimens were used in the 122 patients 
evaluated in the study (summarized in Supplementary Table 1). The most common regimen 
was 90 mg at weeks 0 and 4 (47% of patients). The mean cumulative dose of ustekinumab 
administered during the first month was 149±64 mg. When analyzing the 122 patients into 
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subgroups according to the cumulative ustekinumab dose received during the first two 
months: 39 (32%) patients received a dose lower than 90mg, 74 (61%) patients received a 
dose comprised between 135 and 180mg, and 9 (7%) patients received a dose higher than 
225mg. At inclusion, 18 (15%) patients received concomitant immunosuppressant (11 
thiopurines and 7 methotrexate) and 19 (16%) steroids. Among the 122 patients included, 115 
received at least two injections of ustekinumab; 7 different regimens were administered 
during the maintenance phase (summarized in Supplementary Table 1). The most common 
protocol was 90 mg every 8 weeks in 56/115 (49%) of the patients.  
Efficacy of ustekinumab 
Clinical benefit at three months 
After three months ustekinumab resulted in a clinical benefit in 79/122 (65%) patients 
(Figure 1B). A clinical benefit was obtained in 71/110 (65%) patients treated for luminal CD 
and in 8/12 (67%) patients treated for perianal disease. Among the 19 patients who received 
concomitant steroids when starting ustekinumab, a clinical benefit at three months was 
obtained in 11/19 (58%) patients with a steroid discontinuation in 7 (37%) patients and a dose 
reduction in 4 (21%) patients (Supplementary Figure 1). 
Biologic and endoscopic response to ustekinumab 
Fifty eight patients with a clinical benefit from ustekinumab at the three month follow-
up had elevated CRP at inclusion and a second CRP levels measurement at three month 
follow-up; CRP levels decreased in 55/58 (95%) of these patients, including 24/58 (41%) with 
CRP normalization (below 5 mg/L) (Figure 2A). The median decrease in CRP levels was 18 
mg/L (IQR: 8-32 mg/L).   
An endoscopic evaluation was available in 22 patients at inclusion and at the three 
month follow-up. An endoscopic response was observed in 17/22 (77%) patients, and a 
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mucosal healing in 2/22 (9%) (Figure 2B). Clinical characteristics of the 22 patients with 
repeat endoscopic evaluation are summarized in the Supplementary Table 2. 
Predictive factors of clinical benefit at three months 
The independent predictive factors of benefit from ustekinumab at the three month 
follow-up on univariate and multivariate analysis are shown in Table 2. In multivariate 
analysis, concomitant immunosuppressant at inclusion was the only predictive factor of a 
clinical benefit to ustekinumab at three months (OR 5.43, 95% CI: 1.14- 25.77; p = 0.03). No 
difference was observed in patients receiving thiopurines or methotrexate. 
Clinical benefit at 6 months and 12 months in initial responders to ustekinumab  
The median follow-up in the 79 patients with clinical benefit at three months was 9.8 
months (IQR: 5.3-14.5 months). Among them, the cumulative probability of a persistent 
clinical benefit (without surgery, steroids or immunosuppressant introduction) at 6 and 12 
months by the Kaplan-Meier was 93% and 68%, respectively (Figure 3). Eighteen (23%) of 
the patients with a three month response experienced secondary ustekinumab failure during 
the maintenance phase leading to surgical resection (9 patients), immunosuppressant and/or 
re-administration of steroids (9 patients).  
Six (8%) of the 79 patients with a clinical benefit at three months required 
optimization of ustekinumab. The optimization was performed by doubling the dose in one 
patient who was initially started on 45mg every 12 weeks, and by shortening injection interval 
in 5 other patients: 45mg every 12 weeks to every 6 weeks for three patients, 90mg every 12 
weeks to every 6 weeks in one patient, and 90mg every 8 weeks to every 4 weeks in one 
patient. Ustekinumab optimization was successful in 50% of patients.  
Evolution of patients without a clinical benefit with ustekinumab at three months 
Median follow-up in the 43 non-responders was 4 months (IQR: 2.8-6.2 months).
During the first three months of ustekinumab therapy 12/43 (28%) patients underwent 
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surgery, 8/43 (19%) had immunosuppressant or steroid introduction, and 16/43 (37%) 
permanently stopped ustekinumab treatment. Only 7 (16%) non-responders maintained 
ustekinumab (without surgery, steroids or IS introduction) for more than three months with a 
clinical benefit in 4 of them at 6 months: two achieved clinical benefit after 6 months without 
dose adjustment, receiving 90mg at weeks 0 and 4 and 90mg every 12 weeks in the 
maintenance phase and the two other patients have been optimized by shortening injection 
interval (from every 8 weeks to every 4 weeks).  
Evolution of anti-TNF-induced paradoxical skin lesions 
No patient received ustekinumab treatment for skin adverse event only; however 14 
(11%) patients received ustekinumab for active CD and also had paradoxical anti-TNF 
induced psoriasiform skin lesions. Among them, only two (14%) patients had psoriasis prior 
to anti-TNF treatment. An ustekinumab induced clinical improvement in CD was observed at 
three months in 11 (79%) patients and in skin lesions in 13 (93%).
Safety of ustekinumab 
An adverse event developed in twenty patients (16%) (Table 3). Myalgia and 
infections were the most frequent events, observed in 3% and 7% of patients, respectively.  
One severe adverse event led to ustekinumab withdrawal in a 72 year-old woman with 
CD for 33 years who developed severe pneumococcal pneumonia. One patient presented with 
an allergic reaction (rash, edema, dyspnea), immediately after the second ustekinumab 
injection. Two other patients developed disabling myalgia requiring the discontinuation of 
ustekinumab. Thus, ustekinumab was discontinued in 4/122 patients (3%) because of severe 
infection, myalgia, or intolerance. 
No malignancies or deaths, were reported during follow-up. No injection site reactions 
were observed.  
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DISCUSSION
In the present study evaluating the response to subcutaneous ustekinumab induction 
and maintenance in CD patients with prior and multiple anti-TNF failures, a clinical benefit 
was observed in nearly two thirds of the patients at three months. It was associated with a 
biological and endoscopic response as well as a good safety profile. Interestingly, 
concomitant immunosuppressant therapy was associated with greater efficacy and the clinical 
benefit of ustekinumab was maintained in the first year in most primary responders.  
Ustekinumab has been evaluated in patients with moderate-to-severe CD in two 
randomized placebo-controlled trials and in one cohort study. In a double blind phase IIa 
placebo-controlled trial, the clinical response at week 8 was not better than with placebo. 
However, when patients were stratified for previous infliximab exposure, the response to 
ustekinumab was significantly better in previously treated patients - 59% vs. 26% than in 
placebo (p=0.02).15 A double blind placebo-controlled phase IIb trial, called CERTIFI, was 
performed in anti-TNF refractory CD patients who were randomly assigned to receive 
intravenous ustekinumab (1, 3, or 6mg/kg) or placebo in the 8-week induction phase, then 
initial responders received subcutaneous ustekinumab or a placebo in the 28-week 
maintenance phase.13 At week 6, the clinical response was significantly better in the 6mg/kg 
group than with placebo (39.7% vs. 23.5%; p=0.005), but clinical remission was not 
significantly different between the groups. It should be noted that treatment with two or three 
anti-TNF agents had failed in nearly half the patients in the CERTIFI trial. This is different 
from our cohort which included more severe patients because 91% of them experienced both 
infliximab and adalimumab failure at inclusion. However, the higher proportion of patients 
with clinical benefit from induction with ustekinumab in our series may be related to a less 
strictly defined clinical outcome, a different route of administration and a longer follow-up for 
the assessment of clinical response. Results from a retrospective Canadian cohort of 38 anti-
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TNF refractory CD patients also showed a 74% clinical response to subcutaneous 
ustekinumab at three months.16  
The present study showed that concomitant immunosuppressant therapy may play an 
important role in the efficacy of ustekinumab possibly due to a synergistic 
immunosuppressant effect. As only few patients (15%) received concomitant 
immunosuppressant, this synergistic effect on ustekinumab efficacy should be confirmed 
providing further data from randomized controlled trials.  Although adjustment of the dose of 
ustekinumab for body weight, as recommended in psoriasis patients might also improve the 
clinical efficacy of this drug, 17 a dose effect was not identified as a predictor of response in 
the present study. It has been shown that optimizing treatment can improve the response in 
psoriasis patients receiving ustekinumab as maintenance therapy.18 Moreover, Kopylov et al 
have reported that increasing the dose of ustekinumab was successful in two thirds of CD 
patients who lost the treatment response to this drug.16 In the present study, optimization was 
effective in 50% of the patients. Of note, we reported that ustekinumab maintenance and 
optimization could be effective in patients without initial clinical benefit. These results 
underline that long time exposition to ustekinumab may be necessary. 
Deep remission, defined as clinical remission, biological remission, and mucosal 
healing, has been established as a new therapeutic goal and is associated with more clinical 
remission rates, fewer flares, hospitalizations and surgeries.19 Moreover, it has recently been 
shown that deep remission could be obtained by optimizing medical treatment.20 The present 
study is the largest cohort of CD patients treated with ustekinumab with a composite 
assessment of response (clinical, biological and endoscopic) and showed that the clinical 
benefit of ustekinumab was associated with a biological and endoscopic response in most 
patients. These data emphasize the objective improvement in CD patients treated with 
ustekinumab, and show that ustekinumab is a viable and efficient therapeutic option in anti-
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TNF refractory CD patients. We acknowledge that a limited number of patients from the 
present cohort had an endoscopic assessment, showing an improvement in most of them and a 
mucosal healing in 9% of the patients. Nevertheless, in patients refractory to multiple anti-
TNF therapies, an endoscopic improvement could be considered as a relevant objective.  
Tillack et al. recently reported the results in 7 IBD patients who switched from anti-
TNF treatment to ustekinumab, due to severe psoriasiform skin lesions that did not respond to 
topical treatment requiring discontinuation of anti-TNF. Skin lesions improved in all 
patients.21 In the present study, ustekinumab resulted in improvement in nearly all of the 14 
CD patients with anti-TNF induced psoriasiform skin lesions. However, flare of psoriasis 
lesions with ustekinumab treatment have been described in the literature, suggesting that the 
use of ustekinumab should be carefully managed in CD patients with psoriasiform skin 
lesions induced by anti-TNF therapies22–24. 
 The safety of ustekinumab has been evaluated in more than 3000 patients with chronic 
immune-mediated-inflammatory diseases (IMIDs) included in controlled trials.25 In the phase 
III placebo-controlled trial performed in patients with moderate-to-severe psoriasis,18,26
adverse events were comparable in the placebo and ustekinumab groups after a 5 year follow-
up duration. Infections including respiratory tract infections and nasopharyngitis were the 
most common adverse event reported; they were mild and did not require ustekinumab 
withdrawal. Injection site reactions were rare and occurred in an estimated 1-2% of patients. 
The rates of severe infections and malignancies were low and similar in the placebo and 
ustekinumab groups. There were no reported cases of tuberculosis. In the CERTIFI trial, the 
occurrence of adverse events in the placebo and ustekinumab groups were comparable and 
one basal-cell carcinoma was reported in the ustekinumab group.13 In the present study, 
ustekinumab was found to be safe and well tolerated with only one serious adverse event 
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(pneumonia) and 4 cases (3%) of ustekinumab withdrawal due to severe infection or 
intolerance reactions. No injection site reactions or malignancies were reported. 
The present study has limitations due to its retrospective design. First, although 
validated clinical scores of disease activity were not used as a primary endpoint, clinical 
benefit was determined by physicians from tertiary centers. Moreover objective outcomes 
including biological and endoscopic findings were also analyzed. Despite several different 
ustekinumab induction and maintenance regimens, most patients received high doses of 
treatment showing the probable benefit of a subcutaneous ustekinumab induction regimen in 
CD.  
In conclusion, subcutaneous ustekinumab was effective and well tolerated in a selected 
cohort of patients with active CD and previous and multiple anti-TNF failures. Pending 
results from ongoing clinical trials and other series, ustekinumab should be considered in 
patients with CD that is refractory to currently licensed drugs. 
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TABLES
Table 1: Demographic and clinical characteristics N= 122 
Female, n (%) 87 (71%) 
Median age (IQR) at time  
of ustekinumab introduction (y)
33.8 (27.5-43.9) 
Median disease duration (IQR) at time  
of ustekinumab introduction (y) 
11.5 (6.9-17.1) 
CD location (Montreal classification), n (%)
           L1 15 (12%) 
           L2 19 (16%) 
           L3 87 (71%) 
           L4 16 (13%) 
           Perianal 71 (58%) 
CD phenotype (Montreal classification), n (%)
           Inflammatory 61 (50%) 
           Stricturing 27 (22%) 
           Penetrating 34 (28%) 
Smoker status, n (%)
           No smoker 65 (53%) 
           Former smoker 16 (13%) 
           Current Smoker 41 (34%) 
Previous intestinal resections, n (%) 75 (62%) 
Previous immunosuppressant, n (%) 119 (98%) 
           Thiopurines 113 (93%) 
           Methotrexate 78 (64%) 
Previous anti-TNF, n (%) 122 (100%) 
           Infliximab 118 (97%) 
           Adalimumab 111 (91%) 
           Certolizumab pegol 44 (36%) 
Other previous medications, n (%)
           Ciclosporin 5 (4%) 
           Thalidomide 6 (5%) 
           MycophenolateMofetil 2 (2%) 
           Cyclophosphamide 3 (3%) 
           Sirolimus 2 (2%) 
           Tacrolimus 5 (4%) 
           Golimumab 5 (4%) 
Reason of ustekinumab introduction, n (%)
          Luminal disease 110 (90%) 
          Perianal disease 12 (10%) 
Concomitant immunosuppressant, n (%) 18 (15%) 
         Thiopurines 11
         Methotrexate 7
Concomitant steroids, n (%) 19 (16%) 
CRP level at the initiation, n=104 (%)
         CRP <5mg/L 32 (31%) 
         CRP >5mg/L 72 (69%) 
Abbreviations: CD, Crohn’s disease; TNF, Tumor Necrosis Factor; CRP, C-reactive protein; 
y, years; n, number of patients 
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Table 2: Univariate and multivariate logistic regression analysis of factors predicting 
clinical benefit to ustekinumab at 3 months 
Factors predicting 
ustekinumab response 
Univariate odds 
ratio (95% CI) 
p
value 
Multivariate odds 
ratio (95% CI) 
p
value 
Female gender 1.58 (0.70 - 3.57) 0.26 - 
Age 0.74 (0.35 - 1.59) 0.44 - 
CD duration 0.81 (0.38 - 1.70) 0.57 - 
Perianal CD 0.91 (0.43 - 1.95) 0.81 - 
Smoker status 0.92 (0.41 - 2.09) 0.84 - 
Previous resection 0.79 (0.36 - 1.71) 0.54 - 
Reasons for ustekinumab 
introduction (luminal/anal) 
1.10 (0.31 - 3.90) 0.88 - 
Concomitant steroids at time 
of ustekinumab introduction 
0.49 (0.17 - 1.44) 0.19 - 
Concomitant 
immunosuppressant at time 
of ustekinumab introduction 
5.21 (1.09 - 24.85) 0.02 5.43 (1.14 - 25.77) 0.03 
C-reactive protein > 5mg/L 0.44 (0.16 - 1.17)  0.09 0.37 (0.14 - 1.00) 0.06
Mean cumulative first 
month’s dose 
0.89 (0.42 - 1.90) 0.78
Ustekinumab dose received 
during the first two months  
≤ 90mg 1 - 
          135-180mg 1.82 (0.68 - 4.83) 0.22 - 
≥ 225mg 2.27 (0.51 – 10.08) 0.27 - 
Abbreviations: CI, confidence interval; CD, Crohn’s disease. 
Bold value indicates statistically significant odds ratios in the multivariate analysis.  
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Table 3: Adverse events related to ustekinumab  
No. of patients SAE Discontinuation of 
ustekinumab 
Patients with any adverse events, n (%) 20 (16%) 1 (1%) 4 (3%) 
Serious infections
    Severe pneumococcal pneumonia 1 1 1
Infections
    Folliculitis 1
    Staphylococci 1
    Bronchitis 1  
    Sinusitis 1
    Pneumonia 1
    External otitis 1
    Rhino pharyngitis 1
    Urinary tract infection 1
Cutaneous adverse event
    Eczema 2
    Psoriasis 1  
Other adverse events 
    Arthralgia 3
    Myalgia 3 2
    Depression 1
Allergic reaction 1 1
Injection site reaction 0
Malignant disease 0
Death 0
Abbreviation: SAE, severe adverse event.
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FIGURE LEGENDS  
Figure 1: Flowchart of the patients in the study. (A) Disposition of all included patients 
receiving subcutaneous ustekinumab. (B) Disposition of all included patients with a clinical 
response assessment to ustekinumab at 3 months.  
Figure 2: (A) Proportions of patients with a C-reactive protein (CRP) decrease or CRP 
normalization among the 58 patients with clinical benefit to ustekinumab and having two CRP 
evaluations at time of ustekinumab introduction and at 3 months. (B) Proportions of patients 
with an endoscopic response or a mucosal healing at 3 months among the 22 patients with 
clinical benefit to ustekinumab and having two endoscopic evaluations at time of ustekinumab 
introduction and at 3 months. Numbers of patients are indicated below the histograms.  
Figure 3: Kaplan-Meier survival curve of failure-free response to ustekinumab among the 79 
initial responders at 3 months. The median follow up duration was 9.8 months (interquartile 
range: 5.3-14.5 months). 
Supplementary Figure 1: Steroid discontinuation and reduction in CD patients with 
ustekinumab clinical benefit at three months.  
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SUPPLEMENTARY MATERIAL 
Supplementary Table 1: Induction and maintenance regimens of ustekinumab                    
Induction regimens, n 122
90 mg week 0/4 58
90 mg week 0 24
45 mg week 0/4 9
90 mg week 0/6  8
45 mg week 0  6
135 mg week 0  4
270 mg week 0 / 90 mg week 4 3
45 mg week 0 / 90 mg week 4 3
135 mg week 0 / 90 mg week 4 2
90 mg week 0/1/2 2
396 mg week 0  1
90 mg week 0/2/4 1
45 mg week 0/2/4 1
Maintenance regimens, n 115
90 mg q 8 weeks 56
45 mg q 12 weeks 18
90 mg q 4 weeks 14
90 mg q 12 weeks 12
90 mg q 6 weeks 9
45 mg q 8 weeks 5
45 mg q 4 weeks 1
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Supplementary Table 2: Clinical characteristics of the 22 patients with repeat 
endoscopic evaluation of response to ustekinumab 
Endoscopic evaluation at 3 months, 
n (%) 
No endoscopic 
response 
3/22 (14%) 
Endoscopic 
response 
17/22 (77%) 
Mucosal  
healing 
2/22 (9%) 
CD location (Montreal 
classification), n (%) 
   
           L1 1 (33%) 3 (18%) 0
           L2 0 4 (23%) 0 
           L3 2 (67%) 10 (59%) 2 (100%) 
           L4 0 0 0
           Perianal 2 (67%) 11 (65%) 0
CD phenotype (Montreal 
classification), n (%) 
   
           Inflammatory 1 (33%) 8 (47%) 2 (100%) 
           Stricturing 2 (67%) 4(24%) 0
          Penetrating 0 5 (29%) 0
Previous anti TNF treatment 3 (100%) 17 (100%) 2 (100%) 
Number of previous anti TNF 
          1 1 (33%) 1 (6%) 2 (100%) 
          2 0 12 (71%) 0
3 2 (67%) 4 (23%) 0 
Reason of anti TNF discontinuation 
Intolerance 1 (6%) 2 (100%) 
Loss of efficacy 1 (33%) 7 (41%) 
Primary failure 1 (6%) 
Both 2 (67%) 8 (47%) 
Concomitant immunosuppressant 
Thiopurines 1 (33%) 2 (12%) 0
Methotrexate 0 1 (6%) 0 
Abbreviations: CD, Crohn’s disease; TNF, Tumor Necrosis Factor; n, number of patients. 
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